Please visit answersincme.com/EZF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the current treatment options for von Hippel-Lindau (VHL) disease. Upon completion of this activity, participants should be better able to: Recognize unmet needs in the management of von Hippel-Lindau (VHL)-associated renal cell carcinoma (RCC); Describe the clinical impact of current guideline-recommended treatment options for VHL-associated RCC; and Identify strategies to manage adverse events arising from systemic treatment options for VHL-associated RCC.